RATIONALE: Stimulation of β3-adrenoreceptors (β3-AR) blunts contractility and improves chronic left ventricular function in hypertrophied and failing hearts in a neuronal nitric oxide synthase (nNOS) dependent manner. nNOS can be regulated by post-translational modification of stimulatory phosphorylation residue Ser1412 and inhibitory residue Ser847. However, the role of phosphorylation of these residues in cardiomyocytes and β3-AR protective signaling has yet to be explored. OBJECTIVE: We tested the hypothesis that β3-AR regulation of myocyte stress requires changes in nNOS activation mediated by differential nNOS phosphorylation. METHODS AND RESULTS: Endothelin (ET-1) or norepinephrine induced hypertrophy in rat neonatal ventricular cardiomyocytes (NRVMs) was accompanied by increased β3-AR gene expression. Co-administration of the β3-AR agonist BRL-37433 (BRL) reduced cell size and reactive oxygen species (ROS) generation, while augmenting NOS activity. BRL-dependent augmentation of NOS activity and ROS suppression due to NE were blocked by inhibiting nNOS (L-VNIO). BRL augmented nNOS phosphorylation at Ser1412 and dephosphorylation at Ser847. Cells expressing constitutively dephosphorylated Ser1412A or phosphorylated Ser847D nNOS mutants displayed reduced nNOS activity and a lack of BRL modulation. BRL also failed to depress ROS from NE in cells with nNOS-Ser847D. Inhibiting Akt decreased BRL-induced nNOS-Ser1412 phosphorylation and NOS activation, whereas Gi/o blockade blocked BRL-regulation of both post-translational modifications, preventing enhancement of NOS activity and ROS reduction. BRL resulted in near complete dephosphorylation of Ser847 and a moderate rise in Ser1412 phosphorylation in mouse myocardium exposed to chronic pressure-overload. CONCLUSION: β3-AR regulates myocardial NOS activity and ROS via activation of nNOS involving reciprocal changes in phosphorylation at two regulatory sites. These data identify a novel and potent anti-oxidant and anti-hypertrophic pathway due to nNOS post-translational modification that is coupled to β3-AR receptor stimulation.
RATIONALE: Stimulation of β3-adrenoreceptors (β3-AR) blunts contractility and improves chronic left ventricular function in hypertrophied and failing hearts in a neuronal nitric oxide synthase (nNOS) dependent manner. nNOS can be regulated by post-translational modification of stimulatory phosphorylation residue Ser1412 and inhibitory residue Ser847. However, the role of phosphorylation of these residues in cardiomyocytes and β3-AR protective signaling has yet to be explored. OBJECTIVE: We tested the hypothesis that β3-AR regulation of myocyte stress requires changes in nNOS activation mediated by differential nNOS phosphorylation. METHODS AND RESULTS:Endothelin (ET-1) or norepinephrine induced hypertrophy in rat neonatal ventricular cardiomyocytes (NRVMs) was accompanied by increased β3-AR gene expression. Co-administration of the β3-AR agonist BRL-37433 (BRL) reduced cell size and reactive oxygen species (ROS) generation, while augmenting NOS activity. BRL-dependent augmentation of NOS activity and ROS suppression due to NE were blocked by inhibiting nNOS (L-VNIO). BRL augmented nNOS phosphorylation at Ser1412 and dephosphorylation at Ser847. Cells expressing constitutively dephosphorylated Ser1412A or phosphorylated Ser847DnNOS mutants displayed reduced nNOS activity and a lack of BRL modulation. BRL also failed to depress ROS from NE in cells with nNOS-Ser847D. Inhibiting Akt decreased BRL-induced nNOS-Ser1412 phosphorylation and NOS activation, whereas Gi/o blockade blocked BRL-regulation of both post-translational modifications, preventing enhancement of NOS activity and ROS reduction. BRL resulted in near complete dephosphorylation of Ser847 and a moderate rise in Ser1412 phosphorylation in mouse myocardium exposed to chronic pressure-overload. CONCLUSION: β3-AR regulates myocardial NOS activity and ROS via activation of nNOS involving reciprocal changes in phosphorylation at two regulatory sites. These data identify a novel and potent anti-oxidant and anti-hypertrophic pathway due to nNOS post-translational modification that is coupled to β3-AR receptor stimulation.
Authors: Klara Brixius; Wilhelm Bloch; Christoph Ziskoven; Birgit Bölck; Andreas Napp; Christian Pott; Dirk Steinritz; Maria Jiminez; Klaus Addicks; Jean-Paul Giacobino; Robert H G Schwinger Journal: Can J Physiol Pharmacol Date: 2006-10 Impact factor: 2.273
Authors: T Angelone; E Filice; A M Quintieri; S Imbrogno; A Recchia; E Pulerà; C Mannarino; D Pellegrino; M C Cerra Journal: Acta Physiol (Oxf) Date: 2008-01-17 Impact factor: 6.311
Authors: Andreas Napp; Klara Brixius; Christian Pott; Christoph Ziskoven; Birgit Boelck; Uwe Mehlhorn; Robert H G Schwinger; Wilhelm Bloch Journal: J Card Fail Date: 2008-10-14 Impact factor: 5.712
Authors: Gerald A Rameau; David S Tukey; Elsa D Garcin-Hosfield; Roseann F Titcombe; Charu Misra; Latika Khatri; Elizabeth D Getzoff; Edward B Ziff Journal: J Neurosci Date: 2007-03-28 Impact factor: 6.167
Authors: Steve R Roof; Hsiang-Ting Ho; Sean C Little; Joseph E Ostler; Elizabeth A Brundage; Muthu Periasamy; Frederick A Villamena; Sandor Györke; Brandon J Biesiadecki; Christophe Heymes; Steven R Houser; Jonathan P Davis; Mark T Ziolo Journal: J Mol Cell Cardiol Date: 2015-01-14 Impact factor: 5.000
Authors: Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai Journal: Basic Res Cardiol Date: 2014-12-06 Impact factor: 17.165
Authors: Hideyuki Sasaki; Takahiro Nagayama; Robert M Blanton; Kinya Seo; Manling Zhang; Guangshuo Zhu; Dong I Lee; Djahida Bedja; Steven Hsu; Osamu Tsukamoto; Seiji Takashima; Masafumi Kitakaze; Michael E Mendelsohn; Richard H Karas; David A Kass; Eiki Takimoto Journal: J Clin Invest Date: 2014-05-16 Impact factor: 14.808